9 years ago
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Using therapeutic antibodies that need to cross the blood-brain barrier (BBB) to treat neurological disease is a difficult challenge. We have shown that bispecific antibodies with optimized binding to the transferrin receptor (TfR) that target β-secretase (BACE1) can cross the BBB and reduce brain amyloid-β (Aβ) in mice.
Continue Reading
http://stm.sciencemag.org
Join the Discussion